Bruno, M.; Ludovisi, M.; Ronsini, C.; Capanna, G.; Stabile, G.; Guido, M.
Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina 2023, 59, 606.
https://doi.org/10.3390/medicina59030606
AMA Style
Bruno M, Ludovisi M, Ronsini C, Capanna G, Stabile G, Guido M.
Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina. 2023; 59(3):606.
https://doi.org/10.3390/medicina59030606
Chicago/Turabian Style
Bruno, Matteo, Manuela Ludovisi, Carlo Ronsini, Giulia Capanna, Guglielmo Stabile, and Maurizio Guido.
2023. "Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR" Medicina 59, no. 3: 606.
https://doi.org/10.3390/medicina59030606
APA Style
Bruno, M., Ludovisi, M., Ronsini, C., Capanna, G., Stabile, G., & Guido, M.
(2023). Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina, 59(3), 606.
https://doi.org/10.3390/medicina59030606
